Pharmeasy Net Profit Growth | Revenue Growth

API Holdings (Pharmeasy)

₹33.00
PLACE ORDER

ROFR Required
No

Available in Depository:
NSDL
CDSL

Available for Investment:
Primary
Secondary

RATING

RECOMMENDATION

Sell

Business Type

Dominant Leader

Investment Checklist

Management

Accounting Practice

Profitability

Solvency

Growth

Valuation

RATING

RECOMMENDATION

Sell

Business Type

Dominant Leader

Pharmeasy Growth

Get info on Pharmeasy Unlisted Shares before buying, selling and investing - Read our Research report on Pharmeasy Peer Comparison & Information like - Revenue Growth, EPS Growth, & Pharmeasy Profitability Ratios.

Pharmeasy Revenue Growth

The company's revenue has grown massively increasing from INR 737.4 Cr in FY'20 to INR 2360.6 Cr in FY'21. This increase is mainly attributable to the massive rise in demand for pharmaceuticals due to the spread the of Covid-19 pandemic across the country.

Pharmeasy Net Profit Growth(PAT)

Despite the company facing a large increase in its revenue in FY'21, the company has faced a larger loss in FY'21 over FY'20. This is due to the large increase in the stock of medicines held by the company , which increased by INR 1511.5 Cr in FY'21 over FY'20. Another reason for increased expenses is the increase in legal consultation and professional fee from INR 29 Cr in FY'20 to INR 87 Cr in FY'21 due to the acquisitions made during the year resulting in increased expenses and further increase in net loss of the company.

Pharmeasy EPS Growth

Pharmeasy EBITDA Growth

The EBITDA of the company has decreased by INR 227.6 Cr in FY'21 over FY'20. This is majorly because of the massive stock purchased by the company in lieu of the high demand of pharmaceutical products due to the pandemic. Another reason for increase in expenses of the company is the increase in employee wages in FY'21.

Pharmeasy Operating Profit Growth

Pharmeasy Asset Growth

The assets of the company have shown a massive growth of 757% in FY'21 over FY'20. This growth in assets is attributable to the increase in cash and cash equivalents which have increased mainly due to the increase in deposit accounts by INR150.0 Cr in FY'21. The major reason of increase in assets is the growth in the goodwill value which has increased from INR 0.7 Cr in FY'20 to INR 3192.1 Cr in FY'21, which is because of the acquisition of Ascent Health as well as Medlife International including its subsidiaries in FY'21.

Pharmeasy Cash Flow from Operations

The cash flow from operations has further decreased by INR 361.6 Cr in FY'21 over FY'20. This is due to the large loss faced by the company in FY'21 as well as the increase in current liabilities which is mainly attributable to the large increase in the company's short term borrowings in FY'21.

Pharmeasy Solvency Ratios

Pharmeasy D/E Ratio

The debt equity of the company is at 0.24 in FY'21 which denotes a very low risk in terms of solvency position of the company. Even thought the total debt of the company has increased to INR 687 Cr in FY'21 which is mainly due to a cash credit loan taken from a bank as well as increase in current maturities of long term debt. But the company's total equity has also had a massive increase which is mainly due to the increase in the security premium reserve increasing by INR 3779 Cr in FY'21. This has increased the other equity of the company which has resulted in the lower debt to equity ratio.

Pharmeasy Current Ratio

The current ratio of the company is 1.63 in FY'21. The current assets of the company have increased by 177% in FY'21 over FY'20 which is because of a large increase in the trade receivables as well as inventory of the company. On the other hand the current liabilities have increased by 665% in FY'21 over FY'20 which is mainly attributable to the increase in short term borrowing of the company as a result of cash credit loan taken from a bank and unsecured loans taken as well in FY'21.

Pharmeasy Quick Ratio

Pharmeasy Interest Coverage Ratio

The company's EBIT has become further negative by INR 242 Cr in FY'21, which is because of the large increase in inventory expenses as well as increase in the remuneration of employees during the year. Due to this the interest coverage ratio has become negative.

Pharmeasy Operating Efficiency

Pharmeasy Operating Profit EBIT Margin(OPM)

The company has a negative EBIT of INR 576 Cr in FY'21 which is due to increased inventory purchase expenses as well as employee remuneration. On the other hand the revenue has increased massively by 220% in FY'21 over FY'20 due to an increased demand for pharmaceuticals and healthcare services in India as a result of the widespread pandemic. Hence the EBIT margin has become negative.

Pharmeasy Profit Before Tax Margin (PBT Margin)

Pharmeasy Profit After Tax Margin (PAT Margin)

The company's net loss has almost doubled increasing from INR 335 Cr in FY'20 to INR 641 Cr in FY'21. This is because the company has faced higher expenses due to higher purchase of inventory to cope with the increased demand arising because of the pandemic as well as higher employee remuneration paid during the year. Another reason for increased expenses is the increase in legal consultation and professional fee due to the acquisitions made during the year. The revenue, on the other hand, has increased massively due to surge in sale of pharmaceuticals due to the pandemic prevalent across the country.

Pharmeasy Profitablity Ratio

Pharmeasy Return on Equity(RoE)

The company has faced a net loss of INR 641 Cr in FY'21 arising despite having higher revenues in the financial year. This is because the company has increased its expenses in order to procure a higher inventory of pharmaceuticals and to pay a higher remuneration to its employees. On the other hand the total equity of the company has increased due to massive increase of INR 3083 in the reserves and surplus. Due to this the ROE is negative.

Pharmeasy Return on Capital Employed(RoCE)

Pharmeasy Return to Assets (RoA)

The company has a negative ROA because the assets of the company have increased 757% in FY'21 over FY'20 majorly due to the increase in the goodwill of the company in FY'21 as a result of the acquisition on Medlife International and Ascent health. The company has faced a net loss in FY'21 due to the large increase in its inventory purchase and employee benefit expenses outweighing the higher revenues in the current year.